The original deal between Pfizer Inc. and Roivant Sciences Ltd. for the tumor necrosis factor-like ligand 1A (TL1A) inhibitor RVT-3101 was perplexing when it happened in December 2022, because Pfizer gave away US rights for the potential blockbuster asset to Roivant for no upfront fee, choosing instead to retain a 25% stake in the company Roivant built to develop the drug, Telavant Holdings, Inc. Now, just 10 months later, Roivant is selling Telavant to Roche Holding AG for $7.1bn.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?